Pure Global: Brazil's IVD Shake-Up & ANVISA's Secret Fast-Track Angle

This episode of LATAM MedTech Insights, brought to you by Pure Global, dives into the landmark regulatory shift just implemented by Brazil's ANVISA. We unpack the new RDC 830/2023 resolution for In-Vitro Diagnostic (IVD) devices, a critical update that redefines market access and compliance in Latin America's largest market. We explore how this harmonization with global standards impacts everything from risk classification to technical documentation. More importantly, we reveal the new strategic 'reliance pathway' that could dramatically accelerate your product's journey to market. Imagine your high-risk diagnostic device, facing a potential year-long review, suddenly becoming eligible for an expedited process in just a few months. This is now a reality for companies with existing approvals from major global authorities, but only if you know how to navigate the new system. Key questions answered in this episode: - What are the specific changes in ANVISA's new RDC 830/2023 for IVDs? - How do I determine if my IVD product's risk class has changed in Brazil? - What is the new 'reliance pathway' and which country approvals make me eligible? - How can leveraging my FDA or Health Canada approval cut my Brazilian registration time by over 70%? - What are the immediate steps my company must take to ensure compliance and avoid market access delays? - Does this change make Brazil a more attractive or more difficult market for IVD manufacturers? At Pure Global, we specialize in turning these complex regulatory updates into clear, actionable strategies. With local experts in Brazil and advanced AI tools, we manage the entire registration lifecycle, helping you leverage new pathways to gain a competitive edge. To ensure your company is prepared for the new era of IVD regulation in Brazil, contact us at [email protected] or visit https://pureglobal.com/.